Purdue Pharma launches no-profit treatment to reverse opioid overdose effects

Five months after the FDA approved Purdue Pharma’s opioid antagonist injection, nalmefene hydrochloride, the no-profit treatment is now available for use, according to a June 21 press release. 

Advertisement

Nalmefene hydrochloride is for a “complete or partial reversal of opioid drug effects,” such as respiratory depression, the press release said.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.